Company news
Poolbeg Pharma Plc (LSE:POLB) news
Poolbeg Pharma Plc news releases on 6ix. Latest, Oct 6, 2026: POLB001 CRS Patent Granted in South Korea
Press releases & updates
POLB001 CRS Patent Granted in South Korea
October 6, 2026
Interim Results for the six months to 30 June 2026
September 29, 2026
POLB 001 TOPICAL trial recruitment update
September 28, 2026
Interim data from POLB 001 TOPICAL clinical trial
September 24, 2026
Key Conference Participation in September 2026
September 3, 2026
Notification of major holdings
July 23, 2026
Notice of Allowance for POLB 001 patent in Israel
July 21, 2026
Placing to raise £3.5 million
July 14, 2026
First patient dosed in POLB 001 TOPICAL trial
July 13, 2026
POLB 001 patent granted in South Africa
June 30, 2026
European patent granted for POLB 001 in CRS
June 16, 2026
Preclinical data posters presented at EHA Congress
June 11, 2026
Results of AGM & Change of Registered Address
June 9, 2026
Pre-IND Meeting with the FDA for POLB 001
May 26, 2026
POLB 001 poster to be presented at EHA 2026
May 13, 2026
POLB 001 CRS patent granted in Canada
May 11, 2026
Results for the year ended 31 December 2025
April 28, 2026
MHRA grants CTA for the POLB 001 TOPICAL trial
April 15, 2026
Significant milestone for Poolbeg's IP portfolio
March 31, 2026
Appointment of Dr Adrian Kilcoyne to SAB
March 12, 2026
Notification of Major Holdings
February 9, 2026
POLB 001 LPS Challenge Trial Paper Published
January 28, 2026
Exercise of Options & Total Voting Rights
January 27, 2026
Letter to Shareholders – 2025 a year of progress
December 18, 2025
POLB 001 to feature in CRS research programme
December 8, 2025
POLB 001 European Patent granted
November 20, 2025
Interim Results for the six months to 30 June 2025
September 29, 2025
POLB 001 Phase 2a Trial Update
September 25, 2025
Director/PDMR Shareholding
June 25, 2025
Results of GM and AGM Meetings
June 23, 2025
FDA Orphan Drug Designation granted for POLB 001
May 27, 2025
Annual Report, AGM Notice & Circular
May 27, 2025
Result of upsized oversubscribed BookBuild Offer
May 23, 2025
Increase of BookBuild Offer
May 22, 2025
Result of Placing and Notice of General Meeting
May 20, 2025
Proposed Retail Offer to raise up to £100,000
May 20, 2025
Proposed Fundraising to raise approximately £4.1M
May 20, 2025
Results for the year ended 31 December 2024
May 20, 2025
Conference Participation in March & April 2025
March 27, 2025
POLB 001 Patent Granted in Korea
March 20, 2025
Termination of proposed combination with HOOKIPA
February 21, 2025
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement reg...
February 20, 2025
Holding(s) in Company
February 18, 2025
Offer Update - Extension to PUSU Deadline
January 30, 2025
Update Potential Combination of Poolbeg & HOOKIPA
January 10, 2025
Combination of Poolbeg and HOOKIPA Pharma Inc.
January 2, 2025
Poolbeg presents POLB 001 data at 66th ASH Meeting
December 9, 2024
POLB 001 Patent Granted in United States
November 20, 2024
POLB 001 data to be presented at ASH
November 6, 2024
Interim results for the six months to 30 June 2024
September 18, 2024